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Poor inclusion rates into clinical trials for teenagers and young adults (TYA; aged 13–24 years) have been assumed but not
systematically investigated in England. We analysed accrual rates (AR) from 1 April 2005 up to 31 March 2007 to National Cancer
Research Network (NCRN) Phase III trials for the commonest tumour types occurring in TYA and children: leukaemia, lymphoma,
brain and central nervous system, bone sarcomas and male germ cell tumours. AR for 2005–2007 were 43.2% for patients aged
10–14 years, 25.2% for patients aged 15–19 years, and 13.1% for patients aged 20–24 years in the tumour types analysed.
Compared with accrual from 1 April 2005 to 31 March 2006, AR between 1 April 2006 and 31 March 2007 increased for those aged
10–14 and 15–19 years, but fell for those aged 20–24 years. AR varied considerably among cancer types. Despite four trials being
available, patients over 16 years with central nervous system tumours were not recruited. Rates of participation in clinical trials in
England from 2005 to 2007 were much lower for TYA older than 15 years compared with children and younger teenagers. The
variations in open trials, trial age eligibility criteria and extent of trial activation in treatment centres in part explain this observation.
Other possible influences, such as difficulties associated with the consent of TYA require further evaluation. Closer dialogue between
those involved in planning and running trials for children and for adults is necessary to improve trial availability and recruitment.
Further research is required to identify trends in trial availability and accrual for those tumours constituting the remaining 26% of TYA
cancers.
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The excellent rates of survival now commonplace for children
affected by cancer have been in part attributed to very high rates of
accrual to clinical trials at diagnosis (Stiller and Eatock, 1999). It
has been estimated that as many as 70% of children in the Western
World will enter a clinical trial (Ablett and Pinkerton, 2003).
Inclusion in clinical trials is widely regarded as being associated
with enhanced quality-of-care, the attention of a broader group of
specialised professionals (Ferrari and Bleyer, 2007), and is seen as
an indicator of an optimum standard of care. Recent data from the
United States have documented a rapid fall-off after the age of 14
years in the proportion of patients enroled in National Cancer
Institute-supported trials and it is this same group that appears to
have gained least from the overall improvements in survival from
cancer experienced by younger children and by adults aged more
than 40 years (Bleyer et al, 2005).
Poor inclusion rates into clinical trials for teenagers and young
adults have been presumed by clinical investigators for some time
but had not systematically investigated in England. We set out to
determine current inclusion rates of those with the most common
cancers occurring in the age range of 13–24 years into National
Cancer Research Network-endorsed (NCRN) clinical trials between
1 April 2005 and 31 March 2007. We wished to compare this with
similar data for children and investigate any factors, which may be
associated with better trial enrolment.
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sMETHODS
We analysed accrual by age to phase III, intervention trials
recruiting newly diagnosed patients with selected tumour types
under the auspices of the NCRN. Similarly, we analysed trials in
selected tumour types from the Children’s Cancer and Leukaemia
Group (CCLG), some of which were not randomised. We included
NCRN-funded studies and other studies approved for inclusion in
the NCRN portfolio (http://public.ukcrn.org.uk/search/Portfolio.aspx?
Level1=1).
We selected cancer subtypes for analysis based on the frequency
of presentation within the following age groups: children (aged
0–12 years) and teenagers and young adults (TYA) (aged 13–24
years). In TYA, lymphomas, brain and central nervous system
(CNS) tumours, germ cell tumours, leukaemia and bone sarcomas
together make up 74% of the newly diagnosed patients (Alston
et al, 2007). To compare accrual rates for children we then
analysed the most common tumour types accounting for a similar
proportion of newly diagnosed tumours in this cohort: leukaemia,
lymphoma, brain and central nervous system tumours which
account for 73% of tumours (Childhood Cancer Research Group,
2007). Trials in these tumour types were selected from the NCRN
and CCLG portfolios. Only trials open for accrual at any time
between 2005 and 2007 were included (NCRN: http://www.ncrn.or-
g.uk). Trials endorsed by the NCRN collect data from 1 April to 31
March each year. We requested accrual data for the same time
periods from CCLG.
We determined the clinical trial availability by manually
searching each trial summary to select study type; study design;
eligibility criteria and current recruitment status. The trials
selected are shown in Table 1. We obtained accrual data for the
selected trials by contacting the trial’s principle investigator. Age at
trial entry for included patients was most often released by the
clinical trial co-ordinator, statistician or data manager. Patients
were then grouped into quintiles corresponding to the 5-year age
groups used by the Office for National Statistics (ONS; 0–4, 5–9,
10–14, 15–19, and so on). We obtained the ages of all patients
recruited to the selected trials, not just those aged 13–24 years. We
were thus also able to compare the inclusion rates of TYA in trials
relevant to their age group with the inclusion rates of older adults
to the same trials. The tumour types analysed account for just 12%
of tumours occurring in those aged 25–59 years (Office for
National Statistics, 2005).
We obtained cancer incidence data from the ONS in 2004, Series
MB1 no. 35, which lists cancer registrations in England (Office for
National Statistics, 2005). The following ICD-10 diagnosis codes
were used: CNS C71, leukaemia C91–C95, Hodgkin’s lymphoma
C81, non-Hodgkin’s lymphoma C82–C85, testis C62, sarcoma C40,
C41. As this was the most recent incidence data available, we
have assumed a similar number of incident cases during the two
12-month periods analysed, 2005–2006, and 2006–2007. The
percentage accrual of patients, or accrual rate, was expressed as the
proportion of patients entered onto the selected trials compared
with the number of new cases diagnosed in 2004.
We applied simple descriptive statistics judging this appropriate
for an observational dataset for which we could not control the
sample size or number of incidence cases. In addition, statistical
comparisons between years and groups could only be deemed
valid if we were able to use real time incidence data rather than
deriving information from the most recent years.
RESULTS
A total of 2608 cases of cancer (excluding non-melanoma of the
skin) were recorded in patients aged 0–24 years in 2004. The
number and proportion of the incident cases with cancer of the
subtypes we selected were 1604 or 61.1% of cases. Figure 1 depicts
the number of patients in England who were entered onto the
selected trials between 2005 and 2007. A total of 1214 patients
aged 0–59 years were enrolled onto trials for the selected tumour
types during 2006–2007, representing 14.3% of 8501 new
diagnoses between the ages of 0 and 59 years for these
selected tumour types during 2004. This is higher than the NCRN
figure of approximately 6.0% accrual to randomised trials
(National Cancer Research Network, 2006) 2006–2007, and is
due to the high accrual rates of paediatric patients through CCLG
centres, compared with TYA and adult tumour types. Accrual rates
for 2005–2006 in the selected tumour types were slightly lower at
13.5% (1148 patients).
The decline in trial participation after 15 years is particularly
notable when trial entry is shown as a proportion of newly diagnosed
cases. This is prominent in both years studied (Figure 2). During
2005–2006 within the tumour types analysed, 39.9% of patients aged
10–14 years (97 of approximately 243 patients) were entered into
clinical trials. This fell to 23.0% for 15–19-year-olds (85 of
approximately 369 patients), and just 13.8% for patients aged 20–
24 years (61 of approximately 442 patients). During 2006–2007
accrual to trials for patients aged 10–14 and 15–19 years improved
by 6.6 and 4.4%, respectively. This was accompanied by a decline of
1.4% in accrual rates for patients aged 20–24 years.
We also divided the cohort into two 10-year age spans to
broadly reflect care within children’s or adult services. New
cancers in the tumour types studied occurred almost twice as often
in those aged 15–24 years (811 cases in the tumour types analysed)
compared with 5 to 14-year-olds (472 cases in the tumour types
analysed). During 2005–2006 the percentage of patients entering
trials changed from 47.8% for ages 5–14 years (226 of
approximately 472 patients), to just 18.0% of patients 15–24 years
(156 of approximately 811 patients). Similarly, between 2006 and
2007 the percentage of patients aged 5–14 years entering trials was
51.3% (242 of approximately 472 patients), compared with 19.2%
of patients aged 15–24 years (156 of approximately 811 patients;
Figure 3). The average over both years shows that approximately
50% of patients aged between 5 and 14 years will be recruited to
trials compared with less than 20% of patients aged 15–24 years
for selected tumour types.
Accrual of TYA was lower than that for children in the following
tumour types: leukaemia, CNS tumours, and bone sarcoma
(Table 2). Accrual of TYA only exceeded that of children in male
germ cell tumours (MGCT) where no patients under the age of 14
were recruited to trials during 2005–2007 reflecting the low
incidence rate of this tumour in the 10–14 age group (seven new
cases in 2004). Two trials were open for TYA with MGCT which
have overlapping age eligibility criteria, CCLG GC3, a Phase III
trial for a newly diagnosed extra cranial malignant germ cell
tumour with an upper age limit of 18 and NCRN TE3, a Phase III
trial for male patients with good risk metastatic germ cell cancer of
the testis with age eligibility of 16–50 years. For 2005–2006
accrual for patients aged 20–24 years was just 2.3% (three patients
of approximately 131) compared with 5.2% of patients aged 15–19
years (three patients out of approximately 58; one being recruited
to the CCLG trial and two to the NCRN TE-3 trial).
Few trials were open during 2005–2007 for the commonest
lymphomas affecting children and TYA. For example, there were
no studies for patients aged 0–17 years with Hodgkin’s lymphoma.
Between 2005 and 2006, we found similar accrual of paediatric and
TYA patients to lymphoma trials, 6.3% of patients aged 5–14 years
vs 6.6% of patients aged 15–24 years (Table 2). However, analysis
by quintiles demonstrated a pattern of decline in patients over 15
years (Table 2). Approximately 8.6% of patients aged 10–14 years
(7 of approximately 81 patients) were recruited to trial
between 2005 and 2006. Despite almost twice the incidence of
lymphoma in patients aged 15–19 years, the accrual rates
were almost half that of those aged 10–14 years, with just 4.5%
of patients aged 15–19 years being recruited to trials
(7 of approximately 156 patients). However, accrual rates increase
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sTable 1 Trials included in the analysis, including age eligibility criteria, and status during the reporting period, 1 April 2005–31 March 2007
Portfolio/trial acronym Title Phase
Age
eligibility
criteria
Status
during 1
April 2005–
31 March
2007
Bone sarcoma
EURAMOS-1 A randomised trial of the European and American Osteosarcoma Study Group to optimise
treatment strategies for resectable osteosarcoma based on histological response to pre-
operative chemotherapy
III 40 years Opened
September 06
EUROEWINGS 99
(ET 2000 03)
European Ewing Tumour Working Initiatives of National Groups: Ewing Tumour Studies 1999 III 50 years Open
Brain and central nervous system
LGG 2004
(CNS 2004 03)
Cooperative multicentre study for children and adolescents with low-grade glioma III 0–16 years Open
PNET4
(CNS 2003 05)
A prospective randomised controlled trial of hyperfractionated vs conventionally fractionated
radiotherapy in standard risk medulloblastoma.
III 4–22 years Closed
December
2006
SIOP Ependymoma
(CNS 1999 04)
SIOP study of combined modality treatment in childhood ependymoma III 3–21 years Open
st PNET
(CNS 2004 01)
Hyperfractionated Accelerated Radiotherapy (HART) with chemotherapy (Cisplatin, CCNU,
Vincristine) for non-pineal supratentorial primitive neuroectodermal tumours
III 3–18 years Open
Germ cell (male)
BEP Continuous infusional
bleomycin – TE3
A randomised phase III toxicity study of day 2,8,15 short (30m ) vs day 1,2,3 long (72 hours)
infusion bleomycin
III 16–50 years Open
GC 3
(GC 2005 04)
Protocol for the treatment of extracranial germ cell tumours in children and adolescents III 0–18 years Opened May
2005
Leukaemia
AML 15 Medical Research Council working parties on leukaemia in adults and children. Acute myeloid
leukaemia trial 15
III o 60 years Open
EsPhALL European Intergroup Study on post induction treatment of Philadelphia positive acute
lymphoblastic leukaemia with imatinib
III o 18 years Open
MRC CLL5 The value of autografting younger patients with high risk chronic lymphocytic leukaemia (cll). A
Randomised Phase III Intergroup Trial
III 418 years Open
SPIRIT STI571 Prospective International Randomised Trial. A phase III, prospective randomised
comparison of imatinib 400mg vs imatinib 800mg vs imatinib plus pegylated interferon in
patients with newly-diagnosed chronic myeloid leukaemia.
III 418 years Open
UKALL XII Medical Research Council Trial for adult patients with acute lymphoblastic leukaemia Under 56
years of age. To compare related donor transplant vs autologous transplant vs chemotherapy.
III 15–55 years Closed to Ph
negative
patients
December
2006
UKALL2003 Medical Research Council working party on leukaemia in Children. UK National Acute
Lymphoblastic Leukaemia (ALL) Trial UKALL 2003
III 1–18 years Open
Lymphoma
ALCL 99
(NHL 2000 06)
International protocol for the treatment of childhood anaplastic large cell lymphoma III 0–22 years Open
BNLI MCD vs FMD BNLI-Randomised Control Trial of MCD vs FMD in follicular NHL III 18–70 years Closed April
2006
Mantle Cell P3 A Randomised Controlled Trial of fludarabine/cyclophosphamide combination with or without
rituximab in patients with untreated mantle cell lymphoma
III 418 years Opened
December
2006
PRIMA A multicentre, phase III, open-label, randomised study in patients with advanced follicular
lymphoma evaluating the benefit of maintenance therapy with Rituximab (MabThera) after
induction of response with chemotherapy plus Rituximab in comparison with no maintenance
therapy
III 418 years Closed March
2007
R-CHOP 14 vs 21 A phase III multicentre Randomised Clinical Trial comparing rituximab with CHOP given every
14 days and rituximab with CHOP given every 21 days for the treatment of patients with newly
diagnosed diffuse large B cell non-Hodgkin’s lymphoma
III 418 years Open
BNLI STANFORD V Protocol for a randomised phase III study of the Stanford V regimen, compared with ABVD for
the treatment of advanced Hodgkin’s disease
III 18–60 years Closed March
2008
a
Waldenstom’s study A randomised trial of Chlorambucil vs Fludarabine as initial therapy of Waldenstro ¨m’s
Macroglobulinaemia and Splenic lymphoma with villous lymphocytes
III 418 years Open
Watch and Wait Rituximab in treating patients with newly diagnosed Stage II, Stage III, or Stage IV Follicular Non-
Hodgkin’s Lymphoma
III 418 years Open
Abbreviations: BNLI: British National Lymphoma Investigation; CCNU: Lomustine; FMD: Fludarabine, Mitoxantrone and Dexamethasone; MCD: mitoxantrone, chlorambucil and
dexamethasone; SIOP: International Society of Paediatric Oncology.
aThis trial was suspended prior to closing.
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sagain for patients aged 20–24 years with 8.3% of patients entering
trials (16 of approximately 192 patients). During 2006 and 2007
accrual rates for 10–14 years and 20–24 years fell by 6.1 and 0.5%,
respectively. Accrual for patients aged 15–19 years remained the
same over both time periods.
Brain and other CNS tumours account for approximately 14.3%
of cancers in patients aged 13–24 years (Alston et al, 2007).
Accrual of TYA to relevant trials for the 2-year period 2005–2007
was very low. Four CCLG trials were open recruiting newly
diagnosed patients, the upper age eligibility of these trials ranging
from 16 to 22 years. Accrual by age, in 2-year intervals is shown in
Figure 4 together with trial availability and age eligibility criteria.
No patients over 16 years had been included from opening these
trials until 31 March 2007. There were no open trials during this
period for patients with newly diagnosed CNS tumours aged 23–24
years.
For bone sarcomas there were two large international rando-
mised trials open, one each for Ewing’s tumours (EURO-Ewing’s
99) and osteosarcoma (EURAMOS-1), which together account for
over 90% of bone sarcomas in TYA. These trials have upper age
limits of 50 and 40 years respectively. The first year of accrual data
analysed between 1 April 2005 and 31 March 2006 included only
6 months of accrual data to EURAMOS 1, which opened in England
in September 2005. Accrual to these two trials for patients aged
0–59 years was 4.2% for 2005–2006 and 24.1% for 2006–2007.
A decline in accrual beyond the age of 15 still persists despite an
age eligibility criterion, which spans the TYA age range. Between
2005 and 2006, accrual of 10 to 14-year-olds was 56.3% (nine of
approximately 16 patients), and 22.2% for 15 to 19-year-olds (10 of
approximately 45 patients). Between 2006 and 2007 almost 100% of
patients aged 10–14 years were recruited, falling to 73.3% of
patients aged 15–19 years.
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Figure 1 Number of newly diagnosed cancer patients entered in NCRN and CCLG lymphoma, leukaemia, CNS, bone sarcoma and male germ cell phase
III trials, 1 April 2005–31 March 2007.
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Figure 2 Proportion of newly diagnosed cancer patients entered in NCRN and CCLG lymphoma, leukaemia, CNS, bone sarcoma and male germ cell
phase III trials, 1 April 2005–31 March 2007.
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across all age groups for 2005–2006, (Table 2). Accrual for patients
aged 10–14 years was approximately 100%, falling to 91.5% for
patients aged 15–19 years, with similar accrual rates (92.9%) for
patients aged 20–24 years. However, for 2006–2007 this fell
considerably across all age groups reflecting the closure of the
main study for acute lymphoblastic leukaemia (ALL), UKALLXII,
for a common subset of patients (Philadelphia negative ALL).
During 2006–2007 accrual rates into NCRN and CCLG haematology
portfolios fell from approximately 100% of patients aged 10–14
years, to just 77.5% of patients aged 15–19 years with a further
decline for those aged 20–24 years to 48.2%, which was almost half
the accrual rate compared with 2005–2006 for this age group.
DISCUSSION
Improving recruitment to high quality clinical trials has been a
constant theme in strategies aimed to improve cancer outcomes,
outlined in the NHS Cancer Plan of 2000 and perhaps more
notably in the recent Cancer Reform Strategy 2007 which
specifically refers to age inequalities in clinical trial accrual
(Department of Health, 2000, 2007). Patients in trials, in addition
to potentially receiving improved therapy, may experience a
‘secondary gain’, benefiting from enhanced quality-of-care and the
attention of a broader group of specialised professionals (Ferrari
and Bleyer, 2007). The excellent survival rates now achieved for
many children with cancer relate in some part to high rates of
inclusion in clinical trials. We set out to investigate the extent to
which teenagers and young adults with frequently presenting
tumour types were being recruited into clinical trials supported by
the NCRN and CCLG. No single source of the data was available
and we have developed a methodology which may be used to
monitor changes in accrual in the future. We have shown that
there is a substantial fall in the accrual of patients to trials
beginning after the age of 14 for the tumour types analysed. This is
consistent with data reported from the United States, Italy and
Australia (Bleyer et al, 2005; O’Brien et al, 2006; Ferrari and Bleyer,
2007). The reasons are likely to be complex and multiple and
require further investigation.
We have developed a methodology that allows up-to-date
assessement of age-dependant trial accrual. We have demonstrated
year by year sensitivity to changes in accrual resulting from trials
opening and closing and have not been limited to trials emanating
from a single trial organisation, but rather sought all those that
may be relevant to TYA. Monitoring of interventions to improve
trial accrual will now be possible in an accurate, and timely way.
This approach contrasts with reports from other countries which
have either described accrual rates from several years previously
(Bleyer et al, 2005, 2006) or have not detailed the data sources and
methodology (Ferrari and Bleyer, 2007).
Trials may not be open for all stages of all tumour types at all
times. In the period studied, few if any, trials were available for
some of the cancers that are common in young people, including
Hodgkin’s lymphoma and germ cell tumours. During 2005–2006,
accrual to acute leukaemia trials was very high with little evidence
of an age effect reflecting both broad eligibility criteria and a
committed clinical community. However, this was affected by the
closure of UKALL XII to Philadelphia negative ALL patients with a
significant decrease in accrual across all ages during 2006–2007.
Bone sarcoma trials also have age eligibility criteria spanning the
biological spectrum of osteosarcoma and Ewing’s sarcoma. Despite
this, the accrual rate of 15 to 24-year-olds was approximately half
that of 5 to 14-year-olds in both years analysed. In the UK most
paediatric oncology services care for children up to the age of 16.
The decreased accrual rate in 15 to 24-year-olds may be accounted
for by an altered priority for clinical research in rare cancers in
adult oncology services or a smaller proportion of older patients
meeting other eligibility criteria. Further research is required to
elucidate this.
The criteria which define the age range of patients eligible for
trial entry are an important determinant of accrual. Commonly
these reflect the source of a clinical trial, whether developed by
paediatric or adult investigators rather than the age incidence of
the particular tumour type. We found examples where age
eligibility criteria overlapped between trials, presenting potential
confusion for clinicians and patients. Emergence of data from the
US, France, Holland, UK and now Sweden, have demonstrated that
TYA with acute lymphoblastic leukaemia treated on paediatric
protocols have better event-free survival and overall survival
P
e
r
c
e
n
t
a
g
e
 
o
f
 
n
e
w
l
y
 
d
i
a
g
n
o
s
e
d
 
p
a
t
i
e
n
t
s
 
r
e
c
r
u
i
t
e
d
 
i
n
 
t
h
e
t
u
m
o
u
r
 
t
y
p
e
s
 
s
e
l
e
c
t
e
d
 
 
47.8
51.3
18.0 19.2
0
10
20
30
40
50
60
70
80
90
100
1 April 2005–31 March 2006 1 April 2006–31 March 2007
5–14 years 15–24 years
Figure 3 Proportion of newly diagnosed patients aged 5–14 and 15–24 years entered in NCRN and CCLG lymphoma, leukaemia, CNS, bone sarcoma
and male germ cell phase III trials, 1 April 2005–31 March 2007.
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et al, 2003; De Bont et al, 2004; Hallbook et al, 2006; Ramanujacher
et al, 2007). These data resulted in co-operation within the UK
between paediatric and adult haematologists. Consequently, the
age eligiblity criteria of the current trial for ALL has been
ammended from 18 to 20 and now to 25 years. This co-operation
has resulted in additional accrual of TYA to this trial and may
provide a model for other cancers.
Brain tumours are the most common cause of death from
cancer in 15 to 24-year-olds (Geraci et al, 2007). A recent survival
analysis by Birch et al (2008) has demonstrated there has been no
sustained improvements for TYA with high-grade brain tumours
during 1979–2003. Four trials were open with upper age limits
ranging between 18 and 21 years during the period studied. No
patients over 16 years with brain tumours have been included in
these trials since opening. This clearly demonstrates that measures
beyond the setting of age eligibility criteria appropriate to tumour
biology are required to improve rates of inclusion of young people.
This may include enhanced dialogue between research groups
representing paediatric and adult services during the planning of
new trials.
These data will serve as a benchmark for assessing the success
of measures to improve clinical trial accrual of TYA across
England. The analysis only reflects trials open to recruitment
during 2005–2007. The effect of opening and closing trials is
visible within this first 2-year analysis. Large trials such as the
osteosarcoma study, EURAMOS-1, which did not start accruing in
the UK until September 2005, made a significant improvement to
the overall accrual rate across all ages. However, an age-dependent
effect was still evident. The CCLG germ cell tumour study GC-3,
which did not have all centres activated during 2005–2006, was
also under-represented in the first year of analysis. For this trial,
accrual did not appear to improve markedly as a consequence of
activation of more centres.
We have used cancer incidence data from 2004 as this is most
recently available, but is not concurrent with our accrual data
which is between 1 April 2005 and 31 March 2006. Although it is
unlikely that changes in incidence will have significantly affected
the results, difficulties in the tumour classification used by cancer
registries may have led to inappropriate inclusion of some
tumours, for example some benign brain tumours. Trials may
include patients with only certain stages of disease and we were
Table 2 Percentage of patients entering into trial for TYA-specific tumours aged 0–24 years between 1 April 2005–31 March 2007
Portfolio 1 April 2005–31 March 2006 1 April 2006–31 March 2007 % Change
Bone
0–4 years 0.0 66.6 +66.6
5–9 years 37.5 68.7 +31.2
10–14 years 56.3 100.0 +43.7
15–19 years 22.2 73.3 +51.1
20–24 years 28.6 42.8 +14.2
Children aged 5–14 years 46.9 100.0 +53.1
Older teenagers and young adults, 15–24 years 24.2 63.6 +39.4
Brain and central nervous system
0–4 years 28.4 29.7 +1.3
5–9 years 20.0 32.9 +12.9
10–14 years 18.3 20.7 +2.4
15–19 years 17.9 10.3 7.6
20–24 years 0.0 0.0 0.0
Children aged 5–14 years 19.1 26.3 +7.2
Older teenagers and young adults, 15–24 years 8.6 4.9 3.7
Germ cell
0–4 years 0.0 100.0 +100.0
5–9 years 0.0 0.0 0.0
10–14 years 0.0 0.0 0.0
15–19 years 5.2 3.4 1.8
20–24 years 2.3 3.1 +0.8
Children aged 5–14 years 0.0 0.0 0.0
Older teenagers and young adults, 15–24 years 3.2 3.2 0.0
Leukaemia
0–4 years 84.1 77.7 6.4
5–9 years 99.1 85.5 13.6
10–14 years 100.0 100.0 +0.0
15–19 years 91.5 77.5 14.0
20–24 years 92.9 48.2 44.7
Children aged 5–14 years 100.0 91.3 8.7
Older teenagers and young adults, 15–24 years 92.3 64.5 27.8
Lymphoma
0–4 years 5.0 10.0 +5.0
5–9 years 0.0 3.2 +3.2
10–14 years 8.6 2.5 6.1
15–19 years 4.5 4.5 0.0
20–24 years 8.3 7.8 0.5
Children aged 5–14 years 6.3 2.6 +3.7
Older teenagers and young adults, 15–24 years 6.6 6.3 +0.3
Rates of inclusion of teenagers and young adults
L Fern et al
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sunable to refine the incidence data to account for this, for example
to accurately determine the proportion of patients with good risk
GCT who would be potentially eligible. We also anticipated
reporting accrual data by each National Cancer Research Network
but accurate cancer incidence data in the required age bands was
not available. Further, we encountered concerns about the release
of small case numbers where the identification of individual
patients is seen as a potential hazard.
The data we have presented covers approximately 74% of
TYA tumours. Further study is required to identify trends in
trial availability and accrual for those tumours constituting
the remaining 26% of TYA cancers. We anticipate that trial
participation will be lower for this cohort as the range of
tumour types is greater including early onset of common adult
carcinomas with smaller numbers of incident cases for each
cancer.
TYA are less likely than children to be included in clinical trials
of the most common cancers for their respective age groups.
Improvements in accrual may contribute to improved treatment
outcomes. This may be achieved through giving greater considera-
tion to TYA in the planning of clinical trials and ensuring that
relevant trials are active in centres treating young people.
Particular attention is required to improve trial accrual in cancers
where survival is poor, such as brain and bone tumours.
Recognition of TYA in new performance incentives for cancer
research networks may be an effective tool to improve access and
accrual. A greater degree of centralisation of care for TYA is
expected to result from the implementation of the recommenda-
tions of Improving Outcomes in Children and Young People with
Cancer (National Institute for Clinical Excellence, 2005). This may
overcome some of the organisational difficulties of maintaining
broad trial portfolios in rare tumours. However, these data reflect a
complex interplay of contributing factors including: the breadth of
the national trial portfolio; variation in activation of trials between
centres and networks; difficulties investigating rare cancers and
changing attitudes to consent and participation among young
people. Future research will involve identifying barriers to accrual
and methods to overcome these so that TYA have equal access and
accrual to clinical trials compared with their paediatric and adult
counterparts.
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